Taeun Kang: Beyond Traditional ‘Blood Thinners’ – Cardiovascular and Thrombosis Therapeutics
Taeun Kang, Founder and Chief Growth Officer of Manhattan Signal, shared a post on LinkedIn:
“Pause and Note – Cardiovascular and Thrombosis Therapeutics
As shared previously, I have been spending more time independently researching cardiovascular therapeutics, thrombosis prevention, and emerging RNA-based medicines simply out of personal interest and curiosity around where the biotech and pharmaceutical industries may be heading.
Based on my research, below is a high-level market snapshot that I thought some people in biotech/pharma – and especially families impacted by cardiovascular conditions – may also find interesting.
It appears that the landscape is evolving beyond traditional ‘blood thinners’ into much more targeted next-generation cardiovascular approaches.
Current leaders still include major anticoagulants and antiplatelet therapies such as:
- Eliquis
- Xarelto
- Pradaxa
- Plavix
- Brilinta
At the same time, increasing attention appears to be shifting toward:
- Lp(a)-lowering therapies
- FXIa inhibitors
- RNA-based cardiovascular medicines
- Precision thrombosis prevention
Particularly interesting is the growing focus around Lipoprotein(a) [Lp(a)], which continues drawing attention in cardiovascular risk and thrombosis research.
Some major programs currently being watched across the industry include:
- Pelacarsen – Novartis
- Olpasiran – Amgen
- Zerlasiran – Silence Therapeutics
- Lepodisiran – Eli Lilly
I also found it fascinating how multiple modalities are emerging simultaneously, including:
- siRNA
- Antisense oligonucleotides (ASO)
- FXIa inhibition pathways
The intersection of RNA therapeutics, cardiovascular medicine, and preventative care may become one of the more important biotech themes of the next decade.
Question: How can we speed up these new emerging therapies?
To be continued”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering